Bangladesh Exports Climb 6.3% to $13.1 Billion in First Quarter of FY27, Led by Pharma and Jute

A Quarter That Did Not Start Where It Finished

Bangladesh's merchandise exports reached 13.094 billion dollars in the first quarter of the 2026-27 fiscal year, up 6.34 percent from the 12.313 billion dollars shipped in the same three months of the previous year, according to Export Promotion Bureau figures reported by Dhaka Tribune and UNB. September alone brought in 3.937 billion dollars, a gain of 8.54 percent over September 2025, making it the strongest single month of the quarter. An EPB official credited what the agency called the resilience of Bangladesh's export sector and the sustained confidence of international buyers, and said the bureau would keep pushing diversification, market expansion and product upgrading.

The quarter's finishing strength masks a rockier start. July, the opening month of FY27, actually saw readymade garment exports fall 1.92 percent year on year to 3.89 billion dollars, according to BGMEA figures reported separately. Woven garments fell 3.16 percent and knitwear slipped 0.90 percent that month. BGMEA attributed the dip mainly to an unusually high comparison base, since July 2025 itself had grown 24.67 percent and was one of the strongest single months on record, and pointed to Bangladesh's recurring gas shortage as the most immediate constraint on factory output. Whatever combination of base effects and energy bottlenecks held July back, August and September more than reversed it, turning a quarter that opened in the red for garments into one that closed up 6.10 percent for the full three months.

Garments Still Carry the Load, But Not Alone

Readymade garments brought in 10.578 billion dollars over the quarter, up 6.10 percent, and remain comfortably the largest single category, accounting for roughly four fifths of everything the country shipped abroad. Knitwear grew faster than woven garments, up 6.88 percent against 5.11 percent, and both categories posted even sharper September gains of around 8.5 percent, broadly in line with the overall garment recovery that month. Those numbers alone would make for a solid, if familiar, export story, RMG has driven Bangladesh's export earnings for decades and any quarter it grows is by definition a decent quarter.

What stands out this time is how much faster everything else grew. Pharmaceutical exports jumped 40.39 percent over the quarter and an extraordinary 64.33 percent in September alone, the fastest growth of any category tracked. Jute and jute goods rose 31.55 percent for the quarter, with a 22.72 percent September gain, while leather and leather products climbed 14.74 percent, light engineering 16.51 percent and home textiles 11.94 percent. None of these categories comes close to garments in absolute dollar terms, but their growth rates suggest buyers are increasingly willing to source a wider range of Bangladeshi goods beyond the apparel the country is best known for. The one clear laggard was agricultural products together with frozen and live fish, which posted negative growth for the quarter, though the EPB figures reported did not break out a specific percentage for that decline.

Category	Q1 FY27 value	Q1 growth	September growth
Total exports	$13.094bn	+6.34%	+8.54%
RMG (total)	$10.578bn	+6.10%	+8.56%
Knitwear	$5.963bn	+6.88%	+8.58%
Woven garments	$4.614bn	+5.11%	+8.54%
Pharmaceuticals	-	+40.39%	+64.33%
Jute and jute goods	-	+31.55%	+22.72%
Light engineering	-	+16.51%	-
Leather and leather goods	-	+14.74%	+20.19%
Home textiles	-	+11.94%	-

Turkiye and the Smaller Markets Doing the Heavy Lifting

On the destination side, the United States remained Bangladesh's single largest export market over the quarter, taking 2.591 billion dollars worth of goods, up 11.34 percent from 2.327 billion dollars a year earlier. The United Kingdom followed at 1.370 billion dollars and Germany at 1.218 billion dollars, with both India and Japan, ranked sixth and ninth among destinations, also posting growth, though the underlying figures for those two markets were not broken out in the reporting. The standout, by a wide margin, was Turkiye, where shipments more than doubled, rising 100.11 percent from 105.21 million dollars to 210.54 million dollars, the fastest growth of any major destination tracked.

A market doubling in size from a low base is a different story than the United States adding 11 percent on top of an already enormous base, and it is worth being careful about which kind of growth matters more for Bangladesh's trade balance. The US gain alone, in absolute dollars, is larger than the entirety of what Turkiye now buys from Bangladesh. Still, diversification away from reliance on a handful of Western markets has been a stated goal of trade policy for years, and a market growing fast enough to double in twelve months, even from a modest starting point, is exactly the kind of signal trade officials point to when arguing that diversification efforts are gaining traction rather than just being talked about.

What the Numbers Do Not Settle

The EPB's framing of the quarter, resilience and sustained buyer confidence, is the version of the story that puts the best face on a genuinely solid set of numbers. It is also, notably, a framing that does not address the energy constraint BGMEA flagged just two months earlier, when the same gas shortage blamed for July's RMG dip was described as the biggest limit on factory output, not a one month blip. If gas supply remains tight through the rest of the fiscal year, the kind of month to month volatility seen between July's decline and September's 8.54 percent surge may simply recur, with individual months swinging on production capacity as much as on demand from buyers abroad.

There is also a question the quarterly aggregate cannot answer on its own, whether the fast growing smaller categories, pharmaceuticals, jute, light engineering, are compounding on a genuinely expanding base of new orders, or whether some of that growth reflects one off shipments or contract timing that will not repeat next quarter. A single quarter of 40 percent growth in pharmaceutical exports is an encouraging data point, not yet a trend, and the real test will be whether Q2 FY27 figures, due out around the turn of the year, show these smaller sectors continuing to climb at anything close to this quarter's pace once the low base effects that make percentage gains look so large start to fade.